Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to activate a photoactive pharmaceutical (photosensitizer) to create a photodynamic reaction. Current photodynamic therapy devices out on the market are around 20 years old and the companies that manufacture the devices, do not provide yearly maintenance services for the devices. Therefore, Modulight has developed the multi-indication ML6710i ophthalmic laser platform and the beam shaping unit ML-SLA to address the need for supported PDT equipment and to target the treatment of oncological and various other diseases affecting the posterior of the eye with the capability to provide laser light ranging from 400 nm to 2000 nm depending on the specific customer needs. ML-SLA has been tested to yield a superior beam quality and enable a larger spot size range than any existing beam shaping unit in the market, thus eliminating the need for multi-spot treatment of larger lesions. The device connects to Modulight Cloud services, enhancing treatment planning and post-operative analysis. In addition, the ML6710i laser platform has the capability of including a camera module to record the intra-operative fundus view into Modulight Cloud to further assist in post-operative treatment analysis.
Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and light delivery optics. Bladder is somewhat challenging environment for PDT as it needs to be accessed cystoscopically and lesions might be difficult to target with traditional light delivery optics for example because of their close proximity to bladder entrance. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) also require different illumination methods, so laser parameters and illumination modes need to be designed accordingly.
Modulight has developed its ML7710 laser platform further to optimally support a novel photosensitive drug for treatment of NMIBC in clinical setting. The laser system and its light delivery mechanism enable both focused illumination of localized papillary lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Clinicians have been consulted on feasibility of different illumination modes and other practical matters related to e.g., treatment duration. The optimization of Modulight’s system for NMIBC has also included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder-like environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight Cloud.
Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a high recurrence rate and limited treatment options. Currently best results are achieved when BCG (Bacillus Calmette-Guerin) is used together with photodynamic diagnosis (PDD) and TURBT (trans urethral resection of bladder tumor) but majority of NMIBC still recur after the initial treatment. Even though PDD is commonly used to visualize the lesions as part of a TURBT procedure, photosensitive drug compounds have had limited success in clinical setting partly because of limitations in light sources and light delivery optics.
Modulight has extended its multi-indication laser platform to support the use of a novel photosensitive drug for NMIBC. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) require different illumination methods and laser parameters and illumination modes have been defined accordingly. Laser system has been designed to support both focused illumination of localized lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Light delivery system optimization has included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight cloud. Ongoing work and future plans include treatment monitoring and imaging capabilities integration in treatment flow with the aim to have a comprehensive laser platform that can support white light imaging, fluorescence imaging, and a variety of light-based treatment modalities
Delivery of pharmaceuticals to the eye posterior poses a major challenge in ophthalmology. A promising drug delivery platform is indocyanine green (ICG) liposomes, which absorb near-infrared light resulting in a release of pharmaceutical molecules. The Modulight ophthalmic laser platform has been designed for treatments targeting the eye posterior and can also excite the absorption band of the liposomes. The laser connects with Modulight Cloud, enabling artificial intelligence (AI) based treatment planning by correlating the treatment parameters and success, which could increase the efficacy of future treatments. The same algorithms could deduce which treatment parameters work with which liposomal delivery parameters.
Different wavelength lasers are widely used in ophthalmology for example for selectively heating certain tissues of the eye or unleashing the potential of photoactive pharmaceuticals. The problem with many ophthalmic laser-based treatments such as photodynamic therapy for age-related macular degeneration is that the laser technology is outdated and no longer supported despite the wide clinical use of these therapy modalities. Modulight has developed a configurable cloud-connected ophthalmic laser device that can house any of Modulight’s semiconductor lasers and is wirelessly controlled with an iPad. In addition to novel ophthalmic laser technology, Modulight has also developed a novel beam shaping unit which yields superior beam quality and enables exceptionally large treatment spots eliminating the need for multi-spot treatment for larger lesions.
Photodynamic therapy (PDT) is bringing new, effective, and less invasive, possibilities for cancer treatment. ML7710 (Modulight Inc.) medical laser system offers a platform for performing PDT for multiple indications and drugs. Latest avenue is glioblastoma treatment with 5-Aminolevulinic acid (ALA-5) and 635-nm light, where clinical trials are about to begin. Preliminary work suggests major advantages in treatment control, including active in-situ feedback. ML7710 platform has already proven itself for clinical work with intrabronchial obstructive tumors. Preliminary result with 10 patients show that intrabronchial tumors, that strongly affect both the survival and the performance of the patient, can be significantly reduced with ML7710 operated at 665 nm and sodium chlorine E6 photosensitizer. The aim in most of the patients has been a palliative recanalization of the bronchial lumen in order to alleviate the symptoms such as breathlessness and hemoptysis. The illumination dose for the target area was 50–75 J/cm2. All the patients have received multimodality cancer treatment using other intrabronchial interventions, radiotherapy and chemotherapy as needed. In most of the patients, satisfactory treatment results were achieved and it was possible to restart chemotherapy in several patients. In one patient with local cancer a complete remission was established. PDT has also the advantage that it is possible to give PDT after a maximum dose of radiation therapy has already been used and fewer side effects if used in locally advanced intraluminar lung cancer.
We review the development of the first GaSb-based passively mode-locked VECSEL generating sub-picosecond pulses
at 2 μm wavelength range. The general goal of this development was to leverage the unique features of the mode-locked
VECSELs (i.e. high-average power, sub-ps operation, high repetition rate, low-noise properties) to the 2-3 μm
wavelengths. Such lasers could have a significant impact on the development of practical ultrafast systems required for
frequency-combs, time-resolved molecular spectroscopy, THz generation, or as seeders for optical amplifiers and mid-IR
supercontinuum sources. By using semiconductor gain mirrors and saturable absorber mirrors incorporating
InGaSb/GaSb quantum wells, we have been able to demonstrate a VECSEL producing near transform-limited 384 fs
pulses at a wavelength of 1950 nm. Important part of this development has been focused on understanding the ultrafast
absorption recovery dynamics of the SESAM. An interesting observation is that the absorption recovery time of asgrown
InGaSb SESAMs is within ps range and is not much affected by a change of the growth parameters.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.